Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277455 | 0.97 | PTGER4 (0.50) | PTGER4PTGER3PTGER2 | |
| SCHEMBL14301845 | 0.96 | PTGER4 (0.49) | PTGER4PTGER3PTGER2 | |
| SCHEMBL14781404 | 0.93 | PTGER4 (0.55) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6161954 | 0.93 | PTGER4 (0.55) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5790323 | 0.92 | PTGER4 (0.49) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4685746 | 0.90 | PTGER4 (0.43) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4375308 | 0.89 | PTGER4 (0.46) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5760085 | 0.89 | PTGER4 (0.46) | PTGER4PTGER3PTGER2 | |
| SCHEMBL14030671 | 0.89 | PTGER4 (0.55) | PTGER4 | |
| SCHEMBL1376330 | 0.88 | PTGER4 (0.44) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631355-B1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN INC (US) | 2014-08-13 | — | — | EP | claimed |
| US-7326716-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2008-02-05 | — | — | US | claimed |
| EP-1631355-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | Allergan, Inc. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050171062-A1 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2005-08-04 | — | — | US | claimed |
| WO-2004108215-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. | 2004-12-09 | — | — | US | claimed |
| US-6747037-B1 | TREATING OCULAR HYPERTENSION OR GLAUCOMA; REDUCED SIDE EFFECTS | ALLERGAN, INC. | 2004-06-08 | — | — | US | claimed |
| EP-1631355-B1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-1817033-B1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN INC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7326716-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1817033-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | Allergan, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7179820-B2 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2006058080-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| EP-1631355-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | Allergan, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050171062-A1 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2004108215-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. | 2004-12-09 | — | — | US | disclosed |
| US-6747037-B1 | TREATING OCULAR HYPERTENSION OR GLAUCOMA; REDUCED SIDE EFFECTS | ALLERGAN, INC. | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171062-A1 | Treatment of inflammatory bowel disease | SLC10A2, GUCY1B1, PTGER1 | PTGER4 18/4885PTGER3 8/4885PTGER2 33/4885 |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | PTGIR, PTGER1, PTGS1 | PTGER4 14/4885PTGER3 5/4885PTGER2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.